LH Chart

1 Month

	Date	Diff
	2025-04-25	-0.12 %
LabCorp (LH) stock fell by -0.12% due to concerns surrounding Fortrea Holdings Inc., which disclosed disappointing financial results from its pre-spin-off projects, negatively impacting investor sentiment.
	2025-04-24	+1.98 %
Labcorp (LH) stock rose 1.98% last night, supported by a "Moderate Buy" average rating from analysts and positive adjustments to target prices, indicating confidence in the company's performance amid solid earnings results and ongoing interest from institutional investors.
	2025-04-21	-2.26 %
LabCorp (LH) stock declined by 2.26% following concerns raised by Fortrea Holdings regarding underperforming contracts and financial issues stemming from its spin-off from LabCorp, which negatively impacted investor confidence.
	2025-04-17	-1.56 %
LabCorp (LH) stock fell by -1.56%, which may be attributed to negative developments regarding its former subsidiary, Fortrea Holdings Inc., who recently announced disappointing financial results and concerns about future revenue growth impacting investor sentiment.
	2025-04-08	-2.6 %
Laboratory Co. of America (NYSE:LH) stock fell by 2.6% following a downgrade in Q1 2025 earnings estimates from analyst M. Cherny at Leerink Partners, who revised their prediction down from $3.67 to $3.65 per share.
	2025-04-07	-0.67 %
Labcorp (LH) stock fell by 0.67% despite recent upgrades from analysts, likely due to profit-taking after a series of positive ratings and target price increases rather than negative news about the company's performance. LabCorp (LH) stock declined by 0.67% following concerns over Fortrea Holdings Inc., a company that spun off from LabCorp, which announced disappointing financial results and ongoing challenges with revenue performance from pre-spin contracts. Labcorp (NYSE: LH) stock fell by 0.67% partly due to Schroder Investment Management Group reducing its stake by 24.6%, which may reflect broader concerns among institutional investors regarding the company's performance and outlook.
	2025-04-02	+1.6 %
Shares of Laboratory Co. of America Holdings (LH) rose 1.6% following a consensus rating of "Moderate Buy" from analysts, along with positive earnings reports that beat expectations and a strategic raise in price targets by significant financial firms. Labcorp (LH) stock experienced a 1.6% increase due to significant investments by institutional investors, with LPL Financial LLC boosting its holdings by 63.8% and other funds also increasing their stakes, contributing to positive market sentiment and analyst upgrades.
	2025-03-31	+1.18 %
Laboratory Co. of America (Labcorp, NYSE: LH) stock increased by 1.18% likely due to the continued interest from institutional investors, as evidenced by significant stake increases from various firms, alongside solid earnings performance and a positive outlook following recent analyst upgrades.
	2025-03-28	-0.71 %
Labcorp (LH) stock fell by 0.71% amid concerns over claims that the company is conducting fraudulent Bird Flu tests using PCR, which some critics argue is not a valid diagnostic tool.
	2025-03-26	-0.47 %
LabCorp (LH) stock declined by 0.47% possibly due to negative financial developments related to its spin-off company, Fortrea Holdings, which reported disappointing revenue projections and ongoing challenges affecting its financial performance. Labcorp (LH) stock dropped by 0.47% largely due to the significant decline and bankruptcy filing of 23andMe, a genetic testing company, which has implications for Labcorp given its creditors include the National Genetics Institute, a Labcorp subsidiary.
	2025-03-21	-0.67 %
Labcorp (NYSE: LH) stock declined by 0.67% following a significant reduction in holdings by HighTower Advisors LLC, which cut its stake in the company by 42.5%, indicating decreased investor confidence.
	2025-03-19	+0.02 %
The article discusses an investigation into Fortrea Holdings Inc. by Bragar Eagel & Squire on behalf of its stockholders due to potential federal securities law violations, following disappointing financial results that negatively impacted Fortrea's stock price. Labcorp (LH) stock may have seen a slight increase of 0.02% amid this news, potentially due to a market reaction favoring Labcorp's overall stability as the issues impacting Fortrea, a company that spun off from Labcorp, led to concerns about Fortrea's operations rather than Labcorp itself.
	2025-03-17	+0.38 %
Labcorp (LH) stock rose 0.38% due to increased institutional investments, favorable analyst ratings, and positive earnings reports, reflecting growing confidence in the company’s market performance and prospects.
	2025-03-14	+1.65 %
Labcorp (LH) stock rose 1.65% due to several institutional investors adjusting their positions, with increased investments and positive earnings reports contributing to a favorable outlook for the company. Labcorp (LH) stock rose 1.65% after Raymond James Financial Inc. acquired a substantial new position in the company, reflecting increased institutional investment interest as well as positive analyst ratings and recent earnings performance exceeding expectations.
	2025-03-11	-2 %
LabCorp (NYSE: LH) stock declined by 2.0% likely due to a mix of stock sales by company insiders, which may have influenced investor sentiment and market perception.
	2025-03-10	-3.52 %
LabCorp (LH) stock experienced a decline of -3.52% partly due to insider selling, where key executives, including a director, sold significant portions of their ownership, which might have negatively influenced investor sentiment.
	2025-03-07	-0.41 %
Labcorp (LH) stock declined by 0.41% as Oppenheimer & Co. trimmed its holdings, along with several insider sales and mixed analyst ratings affecting investor confidence.
	2025-03-06	-0.09 %
Labcorp (LH) stock dipped by 0.09% following significant insider selling and mixed analyst price target adjustments, despite recent increases in institutional holdings and a positive earnings report. The stock's decline may be influenced by the perception of insider selling as a negative signal, along with varied analyst opinions on the stock's valuation prospects. Labcorp (LH) stock experienced a slight decline of 0.09% despite an upgrade by Citigroup from "neutral" to "buy" with a raised price target, indicating potential positive outlook, likely influenced by recent insider selling activity and broader market trends.
	2025-02-27	-1.42 %
Laboratory Co. of America (LH) stock declined by 1.42%, driven in part by the significant reduction of holdings by Global Retirement Partners LLC and insider sales of stock, which may have raised concerns among investors about the company's stability and future performance.
	2025-02-26	-0.32 %
Labcorp (LH) stock declined by 0.32% due to various factors, including recent insider sales by key executives, adjustments in institutional holdings, and mixed reactions from analysts on the stock's rating and target price.
	2025-02-20	+0.54 %
Labcorp (LH) stock increased by 0.54% following substantial institutional buying activity, as Principal Securities Inc. and other investors raised their holdings in the company, alongside a recent favorable analyst upgrade and positive earnings report.
	2025-02-19	+0.62 %
Labcorp (LH) stock saw a modest increase of 0.62% after Hims & Hers Health announced its acquisition of Trybe Labs, a move that will enhance competition in the at-home lab testing market and broaden access to personalized healthcare services. The stock's rise may be attributed to positive industry sentiment around advancements in telehealth and lab testing capabilities. LabCorp (LH) stock rose by 0.62% as several hedge funds adjusted their positions, with positive quarterly earnings reported, including a net margin improvement and upcoming dividend payouts, attracting investor interest. Labcorp (LH) stock rose by 0.62% likely due to positive earnings reports that exceeded estimates, favorable support from institutional investors, and recent upgrades in stock ratings from several brokerages.
	2025-02-18	-0.08 %
Laboratory Co. of America Holdings (NYSE: LH) experienced a minor decline of 0.08% amidst mixed investor actions, including a 2.4% reduction in holdings by the New Mexico Educational Retirement Board and various adjustments by large investors. The drop in stock value may be attributed to recent insider selling and strategic re-evaluations by institutional investors, despite the company exceeding earnings expectations and maintaining a positive outlook. Labcorp (LH) stock experienced a slight decline of 0.08% likely due to broader market performance, investor sentiment regarding healthcare stocks, or specific developments impacting the company's partnerships and diagnostic services, as suggested by the context of the article focusing on comparisons between other healthcare stocks.
	2025-02-14	+0.66 %
LabCorp (LH) stock rose by 0.66% despite a downgrade in Q1 2025 earnings estimates, as positive adjustments to its price targets and overall favorable ratings from various analysts strengthened investor confidence and contributed to the stock's upward movement.
	2025-02-11	+0.02 %
LabCorp (LH) stock saw a slight increase of 0.02% following a positive quarterly earnings report that exceeded analysts' expectations, despite a reduction in EPS estimates for the first quarter of 2025 by Leerink Partners. LabCorp (NYSE: LH) stock experienced a slight increase of 0.02%, attributed to positive analyst recommendations, with 12 buy ratings and a boosted price target from Bank of America, indicating strong market confidence in the company's performance following its recent earnings report that surpassed expectations. Laboratory Co. of America (NYSE:LH) stock rose 0.02% following an increase in price targets by multiple analysts, including Piper Sandler raising their target from $240 to $260, alongside positive earnings results, which boosted investor confidence. Labcorp (NYSE: LH) stock rose by 0.02% due to positive quarterly earnings that exceeded estimates and increased institutional investment in the company, reflecting confidence in its performance.
	2025-02-10	-0.48 %
Labcorp (LH) stock fell by 0.48% following a period of mixed institutional trading activity and insider stock sales, which might indicate investor uncertainty or a lack of confidence in the company's short-term prospects despite its recent positive earnings report. Laboratory Co. of America (Labcorp, NYSE: LH) recently saw a 0.48% decline in its stock price despite receiving upgraded ratings from several analysts and reporting earnings that beat expectations, possibly due to profit-taking from insiders who sold significant shares. Labcorp (LH) stock declined by 0.48% partly due to significant selling by institutional investors and company insiders, including Yousif Capital Management LLC reducing their stake by 24.6%, which may have contributed to negative market sentiment surrounding the stock.
	2025-02-07	-0.59 %
Labcorp (LH) stock fell by 0.59% after abrdn plc reported a 10.7% reduction in its stake in the company, sparking concern among investors that could be leading to a decline in share price. Labcorp (LH) stock decreased by 0.59% as of February 7, 2025, following a mix of institutional investment activities and insider selling, which may have influenced market sentiment negatively despite the company reporting a slight earnings beat.
	2025-02-06	-0.9 %
Labcorp (LH) stock declined by 0.9% due to general bearish sentiments in the market, as indicated by broader market declines with notable companies reporting mixed earnings results.
	2025-02-04	-0.48 %
Labcorp (LH) stock experienced a decline of 0.48% despite Barclays raising its target price, attributed to selling activities by company insiders and uncertainties in market sentiment despite positive analyst ratings. Labcorp (LH) stock declined by 0.48% following a significant sell-off of shares by institutional investors, including Robeco Institutional Asset Management B.V. which reduced its holdings by 41.4% in the last quarter. Labcorp (LH) stock fell by 0.48% as investors await its upcoming earnings announcement on February 6th, with analysts projecting a decline in the stock's price target and recent insider selling contributing to negative market sentiment.
	2025-02-03	-0.78 %
Labcorp (LH) stock decreased by 0.78% largely due to insider selling, with significant sales by CEO Adam H. Schechter and EVP Glenn A. Eisenberg, leading to concerns about insider confidence in the company's future performance.
	2025-01-23	+0.77 %
Labcorp (LH) stock rose by 0.77% following significant institutional investments in the company during the fourth quarter, indicating positive sentiment and confidence among large investors regarding its financial performance and future outlook. Labcorp (LH) stock rose by 0.77% following the acquisition of new positions by multiple institutional investors, which reflects increasing investor confidence in the company's financial performance, as demonstrated by its recent positive earnings report and revenue growth. Laboratory Corp. of America Holdings (LH) stock rose by 0.77% due to a combination of positive institutional investor activity, increased revenue and earnings reports, and favorable adjustments to price targets from various brokerages.
	2025-01-22	-0.63 %
Labcorp (LH) stock declined by 0.63% due to insider selling by top executives, which may have raised concerns among investors about the company's future performance amidst mixed analyst ratings and institutional changes in holdings.
	2025-01-21	+2.28 %
Labcorp (LH) stock rose 2.28% as it continues to strengthen its position in the healthcare sector, particularly following its involvement in financing Percipio Health's population health monitoring and management app, which reflects its strategic growth initiatives.
	2025-01-17	-0.09 %
Labcorp (LH) stock decreased by 0.09% due to a broader context of market dynamics affecting small-cap medical companies, specifically during the comparative analysis between Genfit and Voyager Therapeutics, where Genfit was highlighted as having higher potential upside yet lower institutional ownership, suggesting investor sentiment may be shifting.
	2025-01-16	+0.62 %
Labcorp (LH) stock rose 0.62% as the Czech National Bank and other institutional investors increased their holdings, indicating stronger investor confidence and positive market trends following solid quarterly earnings and favorable analyst ratings.
	2025-01-14	+0.17 %
Shares of Laboratory Co. of America (Labcorp) (NYSE: LH) rose by 0.17% as analysts maintain a consensus "Moderate Buy" rating, with several firms increasing their price targets following a recent earnings report that beat expectations. The stock's upward movement can be attributed to positive analyst upgrades, a strong quarterly earnings report showcasing revenue growth and an increase in EPS, as well as a consistent interest from institutional investors.
	2025-01-10	-0.99 %
Labcorp (NYSE: LH) stock fell by 0.99% following a downgrade of its FY2024 earnings estimates by Leerink Partners, which reduced their forecast from $14.59 to $14.53 per share.
	2025-01-07	+2.25 %
Labcorp (LH) stock rose by 2.25% largely due to significant institutional investment, with Versant Capital Management Inc increasing its stake by over 1,193% and other institutional investors also expanding their positions, which positively impacts market confidence and demand for the stock.
	2024-12-27	-0.27 %
Labcorp (LH) stock experienced a slight decline of 0.27%, potentially influenced by broader market dynamics or investor sentiment rather than specific company news, as the article primarily compares Tevogen Bio and Genfit instead.
	2024-12-26	+0.68 %
Labcorp (LH) stock rose by 0.68% following positive developments, including an increase in holdings by Principal Financial Group and upgrades in target prices by multiple equity research analysts, which reflects growing investor confidence in the company's performance and prospects.
	2024-12-24	+0.72 %
Labcorp (LH) stock rose by 0.72% following a significant increase in institutional investment, including Franklin Resources Inc. boosting its stake by 27.3%, as well as positive ratings and price target adjustments from several analysts.
	2024-12-20	+0.72 %
Laboratory Co. of America Holdings (NYSE:LH) saw a 0.72% increase in its stock price due to a consensus rating of "Moderate Buy" from analysts, with positive earnings results and upgrades from multiple research firms contributing to investor confidence.
	2024-12-10	-0.62 %
Labcorp (LH) stock declined by 0.62% following HighTower Advisors LLC's reduction of its holdings in the company by 7.4%, alongside insider selling activities, indicating potential concerns about the stock's performance among major investors.
	2024-12-03	-0.02 %
Labcorp (LH) stock experienced a slight decline of -0.02% as The Manufacturers Life Insurance Company reduced its holdings by 3.0%, signaling potential investor caution and contributing to the downward pressure on the stock. Labcorp (LH) stock declined by 0.02% recently, amid a backdrop of increased insider selling by executives and ongoing institutional investments, which may suggest mixed market sentiment towards the company's future performance. Labcorp (LH) stock experienced a slight decline of 0.02% following a 10.2% reduction in Townsquare Capital LLC's stake in the company, as evidenced by their recent SEC filing, while other institutional investors have also adjusted their positions in various ways.
	2024-11-27	+1.43 %
LabCorp (LH) stock rose 1.43% after Pathstone Holdings LLC significantly increased its stake in the company by 124.5% in the third quarter, alongside positive earnings results that exceeded analysts' expectations and an overall bullish sentiment among institutional investors.
	2024-11-22	-0.21 %
Labcorp (LH) stock declined by 0.21% likely due to market reactions around leadership changes, including the upcoming resignation of CFO Glenn Eisenberg, which may raise concerns over company stability and future direction.
	2024-11-19	-1.01 %
Labcorp's (LH) stock fell by 1.01% amid ongoing comparisons with its competitor Grail, highlighting its superior financial metrics, yet analysts maintain a positive outlook on Labcorp with a consensus target price indicating potential upside. The decline may be attributed to broader market conditions or investor sentiment rather than specific negative performance indicators for Labcorp itself.
	2024-11-12	+0.14 %
Labcorp (LH) stock saw a slight increase of 0.14% partly due to significant institutional buying activity, including an increase in holdings by Verdence Capital Advisors LLC and other investors, indicating positive sentiment and confidence in the company's performance.
	2024-11-08	+1.4 %
LabCorp (LH) stock rose by 1.4% following various institutional investments and an increase in target prices from multiple research firms, indicating growing confidence in its financial performance and future prospects. Labcorp (LH) stock rose by 1.4% due to positive earnings results that exceeded analysts' expectations, increased institutional investment activity, and several analysts adjusting their price targets and ratings favorably for the company.